migraine

News

Lundbeck preps phase 3 for migraine prevention drug

Lundbeck seems to have brought its migraine prevention drug bocunebart back on track with positive data for an intravenous formulation.

Digital

Is DTx finally reaching drug-like efficacy? A Q&A with David...

Click Therapeutics CEO David Benshoof Klein shares thoughts on what's been holding DTx back and why this could be the moment for a breakout.

News

FDA resurrects Satsuma's nasal migraine treatment

More than a year after it was rejected by the FDA, Satsuma Pharma's intranasal migraine therapy Atzumi has been given the go-ahead by the agency.

News

FDA clears first migraine DTx from Click Therapeutics

Click Therapeutics' digital therapeutic (DTx) for migraine prevention has been cleared by the FDA, becoming the first treatment of its type in the US.

News

Pfizer offers $60m to settle prescriber kickback claims

Pfizer has paid $60m to settle US government allegations that its Biohaven unit made improper payments to prescribers of its migraine drug Nurtec ODT.

News

AbbVie faulted for misleading ad featuring Serena Williams

Pharma giant AbbVie has been taken to task by the FDA for running an ad for one of its migraine drugs, featuring tennis star Serena Williams, which the agency says overstates its efficacy.<

Lundbeck preps phase 3 for migraine prevention drug

Is DTx finally reaching drug-like efficacy? A Q&A with David...

FDA resurrects Satsuma's nasal migraine treatment

FDA clears first migraine DTx from Click Therapeutics

Pfizer offers $60m to settle prescriber kickback claims

AbbVie faulted for misleading ad featuring Serena Williams

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

migraine

Editor's Picks